Innovating smarter and kinder medicines
Welcome to ChemKAS Pharmaceutics
The field of Targeted Radiopharmaceutics (TRP) has experienced a dramatic resurgence, marked by the recent approvals of Pluvicto, Xofigo, and Lutathera, transforming it from a niche area into a focal point of scientific and high commercial interest.
Achieving efficacious TRP with an optimised therapeutic profile requires the precise application of fundamental principles.
ChemKAS Pharmaceutics, a theranostic radiopharmaceutical company committed to precision medicine, addresses these core elements through its proprietary molecular platforms.
Focusing on critical unmet medical needs in oncology, ChemKAS Pharmaceutics is developing a comprehensive theranostic pipeline.
This pipeline employs a paired strategy, concurrently developing a radiodiagnostic imaging agent and a therapeutic candidate (Theranostic), including both beta and alpha therapies, for each targeted malignancy.
Our molecular platforms enable significant drug pipeline expansion opportunities against high-value targets.
The company's objective is to introduce first-in-class or best-in-class theranostic solutions through the carefully curated selection of isotopes and targeting agents, tailored to specific clinical applications, thereby advancing the development of effective and safe TRP therapies.
Key areas of innovation:
